H.C. Wainwright lowered the firm’s price target on Korro Bio (KRRO) to $53 from $130 and keeps a Buy rating on the shares. The company reported Q1 results and announced a 20% workforce reduction to extend its cash runway into 2027 from the second half of 2026, the analyst tells investors in a research note. The firm believes Korro’s catalysts are on track but adjusted its model to reflect the “increasingly competitive” alpha-1 antitrypsin deficiency landscape.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio price target lowered to $100 from $115 at H.C. Wainwright
- Strategic Workforce Restructuring and Clinical Advancements Justify Buy Rating for Korro Bio
- Korro Bio reports Q1 EPS ($2.49), consensus ($2.62)
- Korro Bio Announces Strategic Workforce Reduction Plan
- Korro Bio initiated with an Overweight at Cantor Fitzgerald